This study is examining how gender-affirming hormone therapy affects the health of blood vessels and impacts cardiovascular disease risk in transgender women.
Do you qualify?
• Transgender women (i.
e., assigned male at birth but identify as female) taking
estradiol and spironolactone
o Ages 18 to 40 or 50 to 75 years
o In good general health
o Have been on hormones for at least 1 year
o No history of gonadectomy
o No history of cancer, diabetes or heart disease
o Non-smoker (or quit at least one year ago)
Main Procedures Involved: • Blood tests for hormones, cholesterol, clotting factor and other labs • Blood vessel cell collection • Dietary analysis • Physical activity monitor • Questionnaires • Ultrasound of the blood vessels • Measurements of bone mineral density and body composition • Compensation provided
Pilot - A pilot Study is used to obtain information, and work out the logistics and management, deemed necessary for further Research Studies.
Anschutz Health and Wellness
Rocky Mountain Regional VA Medical Center
University of Colorado Hospital
Protocol Number: 18-2258
More information available at ClinicalTrials.gov: NCT04066283
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers